Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivasendocrinology-diabetes-and-growth

Paeds Vivas · endocrinology-diabetes-and-growth

Tall stature and overgrowth syndromes — branching viva

Branching viva on tall stature and overgrowth syndromes: redistributing the tall child from the familial normal variant to the pathological cause using a structured assessment, recognising the Beckwith-Wiedemann tumour-risk fingerprint, distinguishing the syndromic overgrowth disorders, and managing the marfanoid child and the child with growth-hormone excess.

branching clinical structured oral1 min readVerification in progress

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
On this page
Study tools

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
Outpatient clinic: a six-week-old large-for-gestational-age infant with macroglossia, an umbilical hernia, and a left leg that is longer and thicker than the right. The examiner asks: what is the diagnosis, which molecular test confirms it and defines the tumour-risk subgroup, and what is the surveillance plan — then branches to the genetics of overgrowth syndromes, the management of a marfanoid adolescent, and finally to the general principle of how to approach the tall child in clinic.

Opening question

A six-week-old large-for-gestational-age infant has macroglossia, an umbilical hernia, and hemihyperplasia of the left leg. What is the most likely diagnosis, which molecular test confirms it and defines the tumour-risk subgroup, and what is the immediate and long-term surveillance plan? [2] [9]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References4ShowHide
  1. [2]Brioude F, Kalish JM, Mussa A, et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome. Nat Rev Endocrinol, 2018.PMID 29377879
  2. [6]Caro R, Savel P, Moss PI. Evaluation of Short and Tall Stature in Children. Am Fam Physician, 2025.PMID 40531152
  3. [8]Tatton-Brown K, Loveday C, Yost S, et al. Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability. Am J Hum Genet, 2017.PMID 28475857
  4. [9]Maas SM, Vansenne F, Kadouch DJ, et al. Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups. Am J Med Genet A, 2016.PMID 27419809
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousSIADH and disorders of water balance — vivaendocrinology-diabetes-and-growthNextThyroid nodules, goitre and thyroid cancer — vivaendocrinology-diabetes-and-growth